Clinical trials: Transplant;Failure,Kidney
Heart Transplantation, Renal Failure
Rapamycin Use in Calcineurin Inhibitor (CNI)-Free Immunosuppression for Stabilization/Improvement of Renal Function After Heart Transplantation
Clinical Problem: Renal insufficiency after heart transplantation caused by cyclosporine medication was addressed. Current therapeutic approaches include cyclosporine reduction or discontinuation.
- Trial name
- NCT00123331
- Testing
- Cyclosporine discontinuation, Rapamycin medication
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- Heidelberg University
ESRD
Combined Blood Stem Cell and Kidney Transplant of One Haplotype Match Living Donor Pairs.
The Stanford Medical Center Program in Multi-Organ Transplantation and the Division of Bone marrow Transplantation are enrolling patients into a research study to determine if donor stem cells given after a living related one…
- Trial name
- NCT01165762
- Testing
- Immune Tolerance
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Everett Meyer
Quality of Life, Depression
CAPABLE Transplant
The purpose of this mixed methods study is to adapt CAPABLE as CAPABLE Transplant to accomplish two things: 1) To resolve barriers to being classified as active on the Kidney Transplant (KT) waitlist, 2) as a surgical…
- Conditions
- Quality of Life, Depression, End Stage Renal Disease, Disability Physical
- Trial name
- NCT06326905
- Testing
- CAPABLE Transplant- Open Label Pilot, CAPABLE Transplant- Randomized Control Trial
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Johns Hopkins University
Renal Transplant Failure, Cardiovascular Complication
Cardiorenal Effecs of Losartan in Kidney Transplant Recipients
The influence of Losartan to cardiovascular and renal outcomes in patients after renal transplatation.
- Trial name
- CELART (NCT05243446)
- Testing
- Losartan
- Where
- Poland
- Volunteers
- 740 people
- Sponsor
- Medical University of Gdansk
Kidney Failure
Everolimus Monotherapy as Immunosuppression After Liver Transplant
Tacrolimus is the standard immunosuppressive drug used to prevent organ rejection post liver transplant. One side effect of Tacrolimus is nephrotoxicity. Everolimus does not have the nephrotoxicity side effects of Tacrolimus.
- Trial name
- NCT04063865
- Testing
- Tacrolimus, Everolimus
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Indiana University
Kidney Failure
Resistive Index Measurements After Kidney Transplantation
The purpose of this study is to evaluate the prognostic performance of intrarenal resistive index in the first years after kidney transplantation on graft function and on patient and graft survival.
- Trial name
- NCT01879124
- Where
- Belgium
- Volunteers
- 346 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Kidney Transplant, Kidney Transplant Failure and Rejection
(TNX-1500) in Kidney Transplant Recipients
The primary objective is to investigate the safety of TNX-1500, an FC-modified anti-CD154 mAb, in five kidney transplant recipients at 12 months.
- Conditions
- Kidney Transplant, Kidney Transplant Failure and Rejection, Immunosuppression, Immunosuppression After Kidney Transplantation
- Trial name
- TONIX-1500 (NCT07204080)
- Testing
- TNX-1500, Kidney Transplant
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- Ayman Al Jurdi, MD
Chronic Kidney Insufficiency, Kidney Transplantation
EPLErenone in CsA-Treated Recipients (EpleCsAT): Safety
Kidney transplant recipients usually lose their graft by rejection or by immunosuppressive drugs toxicity. In kidney transplantation, calcineurin-inhibitors (including cyclosporine A) are widely used.
- Trial name
- EpleCsAT (NCT01834768)
- Testing
- Eplerenone
- Where
- France
- Volunteers
- 31 people
- Sponsor
- CHU de Reims
Transplant;Failure,Kidney, Kidney Transplant
Study Correlation Between Blood, Tissue Gene Expression, Donor Derived Cell Free DNA and Histopathology in Kidney Transplant Recipients
This study will compare the performance of Gene Expression Profile (GEP)/ Donor derived cell free deoxyribonucleic acid (dd-cfDNA) tests, to the following tests: Molecular Microscope (MMDx) and histopathology (study of changes in…
- Conditions
- Transplant;Failure,Kidney, Kidney Transplant, Kidney Rejection Transplant
- Trial name
- NCT05811468
- Where
- United States
- Sponsor
- Rush University Medical Center
Acute Kidney Injury, Renal Insufficiency, Chronic
Safety of Iodinated Contrast in Liver Transplant Candidates With Decreased Renal Function Undergoing Coronary CT Angiography
This study evaluates the safety of iodinated contrast medium administered to liver transplant candidates with decreased renal function undergoing coronary CT angiography.
- Conditions
- Acute Kidney Injury, Renal Insufficiency, Chronic, Contrast-induced Nephropathy, Liver Transplantation
- Trial name
- NCT03806725
- Testing
- Intravenous administration of iodinated contrast medium for coronary CT angiography
- Where
- United States
- Sponsor
- Stanford University
Graft Rejection, Kidney Failure
Study Of The Safety And Efficacy Of Conversion From A CNI To Sirolimus In Renally-Impaired Heart Transplant Recipients
The primary purpose of this study is to determine whether converting from calcineurin inhibitor (CNI) therapy to sirolimus therapy will be more effective than continuing calcineurin inhibitor therapy with respect to renal…
- Trial name
- NCT00369382
- Testing
- cyclosporine or tacrolimus, sirolimus
- Where
- 23 sites in United States, Australia and 5 more
- Volunteers
- 121 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Kidney Transplant, Kidney Failure
Preventing Delayed Graft Function in Kidney Transplant Patients
The health and quality of life benefits of kidney transplantation are reduced by delayed graft function (DGF). There are a number of modifiable risk factors associated with DGF, such as intraoperative hypotension, the type of…
- Conditions
- Kidney Transplant, Kidney Failure, Kidney Injury
- Trial name
- PDF (NCT06724211)
- Testing
- Treatment bundle of care, Control Group
- Where
- 2 sites in Canada
- Volunteers
- 50 people
- Sponsor
- University Health Network, Toronto
Brain Death, Chronic Renal Insufficiency
N-acetyl-cysteine (NAC) and Kidney Graft Function
The goal of this study is to evaluate the effect of N-acetyl-cysteine (NAC) administration in organ donors on the kidney graft function of recipients.
- Trial name
- NCT00998972
- Testing
- N-acetylcysteine
- Where
- France
- Volunteers
- 236 people
- Sponsor
- Institut d'Anesthesiologie des Alpes Maritimes
Coronary Artery Disease
The Use of Aging Biomarkers to Predict Adverse Outcomes After Cardiac Surgery
Cardiac surgery associated acute kidney injury (CSA-AKI) has been recognized as the second most common cause of hospital acquired AKI.
- Trial name
- NCT02496234
- Where
- United States
- Volunteers
- 186 people
- Sponsor
- Sapere Bio
Chronic Kidney Disease Stage 2, Chronic Kidney Disease Stage 3
Preserving Kidney Function in Children With Chronic Kidney Disease
Pediatric chronic kidney disease (CKD) results from health conditions that reduce kidney function for >3 months. It can progress to end-stage kidney disease (ESKD), which requires dialysis or kidney transplant.
- Conditions
- Chronic Kidney Disease Stage 2, Chronic Kidney Disease Stage 3, Pediatric Kidney Disease
- Trial name
- PRESERVE (NCT05169411)
- Testing
- Blood pressure, Urine protein
- Where
- United States
- Volunteers
- 20,240 people
- Sponsor
- Children's Hospital of Philadelphia
PAD - Peripheral Arterial Disease, AAA - Abdominal Aortic Aneurysm
Retrospective Post-Market Clinical Follow-Up Study of GORE-TEX® Vascular Grafts and GORE® PROPATEN® Vascular Graft in Peripheral Artery Disease, Aortic Aneurysms, and Dialysis Access
This multicenter, single-arm retrospective registry (chart review) is being conducted to confirm the clinical performance and safety of GORE-TEX® Vascular Grafts and GORE® PROPATEN® Vascular Graft throughout the device functional…
- Conditions
- PAD - Peripheral Arterial Disease, AAA - Abdominal Aortic Aneurysm, End-Stage Renal Disease
- Trial name
- NCT05124184
- Testing
- GORE® PROPATEN® Vascular Graft, GORE-TEX® Vascular Grafts
- Where
- 8 sites in France, Italy and 1 more
- Volunteers
- 356 people
- Sponsor
- W.L.Gore & Associates
Kidney Transplantation, Kidney Disease
Prediction of Chronic Allograft Nephropathy
The investigators have shown that epithelial-to-mesenchymal transition (EMT) markers in early protocol biopsies of the renal allograft predicts the progression of fibrosis during the first year post-transplantation.
- Conditions
- Kidney Transplantation, Kidney Disease, Kidney Failure, Chronic
- Trial name
- Prefigur (NCT01380847)
- Testing
- mRNAs encoding genes
- Where
- France
- Volunteers
- 300 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Acute Kidney Injury, Acute Renal Injury
Renal and Cardiac Risk Factors of AKI After Liver Transplantation
Background: Liver transplantation (LT) is an extensive operation with various factors contributing to the development of acute kidney injury in the perioperative period.
- Conditions
- Acute Kidney Injury, Acute Renal Injury, Liver Transplant; Complications
- Trial name
- NCT05666232
- Testing
- renal resistive index and myocardial performance index
- Volunteers
- 105 people
- Sponsor
- Mansoura University
End-Stage Kidney Disease
Transplantation of Uncontrolled DCD Kidneys REconditioned by a Novel Ex-VIVo Perfusion MEthod
Eight patient will be transplanted with kidneys from donors dying after uncontrolled circulatory arrest (uDCD), with prolonged warm ischemia (up to 4,5 hours), preserved by a new method based on removal of fibrinogen/fibrin in…
- Trial name
- REVIVEME (NCT05703633)
- Testing
- uDCD treatment
- Volunteers
- 8 people
- Sponsor
- Sahlgrenska University Hospital
Renal Transplant Failure and Rejection
A Study Comparing Siplizumab With Rabbit Anti-Thymocyte Globulin to Help the Body Accept a Kidney Transplant
The goal of this clinical trial is to learn if siplizumab can prevent rejection of a kidney transplant in adult participants with end stage kidney disease.
- Trial name
- MODERNIZE1 (NCT07508787)
- Testing
- Siplizumab, Rabbit anti-thymocyte globulin
- Where
- 14 sites in United States, Brazil and 1 more
- Volunteers
- 120 people
- Sponsor
- Nefro Avillion Clinical Development, LLC